Trial Profile
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (SESAD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms SESAD
- 09 Apr 2024 Planned End Date changed from 1 Jul 2024 to 31 Jul 2025.
- 09 Apr 2024 Planned primary completion date changed from 1 Jul 2024 to 31 Jul 2025.
- 02 May 2022 Planned initiation date changed from 1 Mar 2022 to 1 May 2022.